Latest Funding News

SportsHero Limited has arranged a $1 million unsecured loan facility to support its working capital needs, with flexible monthly drawdowns and a fixed 10% interest rate. The company has already drawn $100,000 from this facility, signaling ongoing liquidity management efforts.

Memphasys Limited marks a pivotal quarter with the completion of clinical trials for its Felix™ System, strategic market expansions in Greater China and the Middle East, and a successful capital raise to fuel growth.

Stavely Minerals has reported significant progress in its copper and nickel exploration projects, highlighting promising assay results and new structural insights that could unlock major resource expansions.

Peregrine Gold secures a significant $1 million commitment from its largest shareholder, Yandal Investments, strengthening its entitlement offer ahead of the project sale to Capricorn Metals.

Peregrine Gold Limited has updated its prospectus to reveal a significant increase in share commitments from its largest shareholder, Yandal Investments, alongside key directors’ participation in the capital raise.

Discovery Alaska Limited is actively assessing new project opportunities and reviewing strategies for its key Alaskan gold assets, while maintaining cautious financial management with limited cash reserves.

Australian Rare Earths Limited has secured a $5 million government grant to advance its Koppamurra Rare Earths Project, while initial drilling at its Overland Uranium Project validates promising geological models for uranium deposits.

Godolphin Resources reports significant drilling success at Lewis Ponds with thick massive sulphide intersections and advances its Narraburra Rare Earths project with high-value carbonate samples, supported by a strong capital raise.

Neometals Ltd has bolstered its financial position with a A$7.1 million capital raise while progressing key projects including the commissioning of a lithium-ion battery recycling plant in Germany and preparing for maiden gold drilling at Barrambie.

InhalerX Limited reported a negative cash flow for the December quarter despite securing a substantial $38.5 million funding facility aimed at advancing its clinical trials. The company has yet to draw on this facility, maintaining a cautious cash position as it progresses its drug development programs.

InhaleRx has locked in a $38.5 million funding deal with Clendon Biotech Capital, enabling expanded Phase 2 trials for its inhaled breakthrough cancer pain and panic disorder treatments. The company also filed a key international patent, positioning itself for a faster path to FDA approval.

Nyrada Inc. reports promising preclinical results for its lead drug NYR-BI03, showing an 86% cardioprotective effect, alongside a strong financial position bolstered by a AU$3.29 million capital raise. The company has submitted its Phase Ia clinical trial package, setting the stage for human testing.